<DOC>
	<DOCNO>NCT02324088</DOCNO>
	<brief_summary>To evaluate benefit add docetaxel-5 fluorouracile ( D-5FU ) regimen pre-operative epirubicin-cyclophosphamide ( EC ) loco-regional treatment inflammatory breast cancer ( IBC ) .</brief_summary>
	<brief_title>Interest Maintenance Chemotherapy After Induction Treatment Inflammatory Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>histologically prove breast cancer inflammatory breast cancer metastatic site age &gt; = 18 &lt; = 60 OMS score : 0 , 1 , 2 life expectancy &gt; = 3 month Normal ( isotopic ultrasonography ) leave ventricular ejection fraction Normal haematological , liver , kidney function patient give write informed consent . non inflammatory breast tumour cutaneous permeation nodule presence metastatic site medical history cancerous tumour except carcinoma situ uterine cervix , basal cell skin cancer , breast carcinoma contralateral side patient already chemotherapy , radiotherapy , hormone therapy breast tumour medical history congestive heart failure even medically control medical history myocardial infarction 6 month inclusion study active infection severe underlie pathology could possibly prevent patient receive treatment administration another chemotherapy study pregnant breast feeding patient ( patient childbearing age must place efficient contraception ) patient whose social psychological state allow consider correct adherence treatment require medical followup WHO score 3,4 unbalanced diabetes polysorbate 80 allergy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>